 CAMBRIDGE, Mass., Sept. 27, 2021 GLOBE NEWSWIRE -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer and Andrew Bellinger, M.D., Ph.D., chief scientific officer and chief medical officer, will participate in a fireside chat during the Chardan Virtual 5th Annual Genetics Medicines Conference on Monday, October 4, 2021 at 11:00 a.m. ET. Dr. Kathiresan will also participate in a panel titled, Genetic Medicines: The Ongoing Emergence of the Heart as a Target Tissue Panel on Monday, October 4, 2021 at 3:00 p.m. ET. 